comparemela.com

Latest Breaking News On - Byjennifer byrne - Page 13 : comparemela.com

At Moonshot forum, expert in early-onset colorectal cancer calls for greater trial funding

Cathy Eng, MD, FACP, FASCO, joined a panel of experts at the White House Cancer Moonshot Colorectal Cancer Forum in highlighting the need for greater patient participation in and funding for cancer clinical trials.Eng, the David H. Johnson professor of surgical and medical oncology at Vanderbilt University, described the panel discussion last month as very productive. Other participants

Sleep disorders among cancer survivors: A massive issue with long-term implications

Sleep disorders are among the biggest issues patients with cancer and survivors face, yet research on interventions to address these disorders remains sparse, according to speakers at National Comprehensive Cancer Network Annual Conference.“A study out of Finland published about 2 years ago looked at a group of survivors and compared them [with] age-matched individuals without cancer in the

Phase 3 study of lung cancer regimen designed to be a model for increasing trial diversity

Researchers have begun enrolling patients in Pragmatica-Lung, an NCI-supported phase 3 study designed specifically to eliminate barriers to clinical trial accessibility and participation.The trial, also known as S2302, will evaluate a two-drug combination for patients with advanced non-small cell lung cancer. It will be among the first NCI-supported trials to use a pragmatic trial design aimed at

Nobel laureate takes pride in success of bioorthogonal chemistry for cancer treatment

It’s not often that a 2 a.m. phone call marks the highlight of someone’s career.“It woke me up, and I looked at the phone and saw the call was from Sweden,” Carolyn R. Bertozzi, PhD, told Healio. “It was a shocking, surreal experience to receive that phone call.’’

Comprehensive molecular testing in lung cancer absolutely crucial yet underutilized

Precision medicine has shown great potential to improve treatment outcomes and prolong survival of patients with lung cancer, as biomarker-driven therapies continue to extend their reach in this space.According to International Association for the Study of Lung Cancer, more than half of patients with lung cancer have tumors that harbor potentially actionable driver mutations. Therapies targeting

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.